The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Launches collaborative centre for translational research in head and neck cancer
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Subscribe To Our Newsletter & Stay Updated
